Saltar al contenido
Merck

Saltar a

1356836

USP

Lamivudine

United States Pharmacopeia (USP) Reference Standard

Sinónimos:

2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas
Tamaño de envaseSKUDisponibilidadPrecio
200 mg
Comprobar disponibilidad del carrito
$447.000

Acerca de este artículo

Fórmula empírica (notación de Hill):
C8H11N3O3S
Número CAS:
Peso molecular:
229.26
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

$447.000


Comprobar disponibilidad del carrito

Solicite una orden a granel
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


grade

pharmaceutical primary standard

API family

lamivudine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI

1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

InChI key

JTEGQNOMFQHVDC-NKWVEPMBSA-N

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lamivudine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Abacavir and Lamivudine Tablets
  • Abacavir, Lamivudine and Zidovudine Tablets
  • Lamivudine
  • Lamivudine and Zidovudine Tablets
  • Lamivudine Oral Solution
  • Lamivudine Tablets

Biochem/physiol Actions

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI).
Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 1

Este artículo
BP802Y0000518BP857
Lamivudine British Pharmacopoeia (BP) Reference Standard

BP802

Lamivudine

manufacturer/tradename

USP

manufacturer/tradename

BP

manufacturer/tradename

EDQM

manufacturer/tradename

BP

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical
pharmaceutical small molecule

format

neat

format

neat

format

neat

format

mixture

API family

lamivudine

API family

lamivudine

API family

lamivudine

API family

lamivudine


Still not finding the right product?

Explore all of our products under


pictograms

Health hazard

signalword

Warning

Clase de almacenamiento

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

target_organs

Blood

Hazard Classifications

Aquatic Chronic 3 - Repr. 2 - STOT RE 2



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Youwen Tan et al.
PloS one, 7(3), e32789-e32789 (2012-04-06)
Several recent reports have demonstrated that tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D) (YMDD) motif mutations can naturally occur in chronic HBV patients without antiviral treatment such as lamivudine therapy. This paper aims to assess the overall spontaneous incidence and
Lior H Katz et al.
The Cochrane database of systematic reviews, (7)(7), CD006005-CD006005 (2010-07-09)
Recurrence of hepatitis B virus (HBV) infection in the liver graft is a grave complication following liver transplantation for HBV cirrhosis. Hepatitis B immunoglobulin (HBIg) seems effective in increasing survival after liver transplantation. HBIg and anti-viral drugs are given alone
Gi-Ae Kim et al.
Gut, 63(8), 1325-1332 (2013-10-29)
Little is known about the long-term clinical outcome and durability of HBsAg seroclearance following nucleos(t)ide analogue (NUC) therapy in patients with chronic hepatitis B (CHB). During a median follow-up period of 6 years (33 567 patient-years) of 5409 CHB patients who were



Número de artículo de comercio global

SKUGTIN
1356836-200MG04061838730893

Questions

Reviews

No rating value

Active Filters